A detailed history of Morgan Stanley transactions in Ventyx Biosciences, Inc. stock. As of the latest transaction made, Morgan Stanley holds 332,677 shares of VTYX stock, worth $755,176. This represents 0.0% of its overall portfolio holdings.

Number of Shares
332,677
Previous 630,777 47.26%
Holding current value
$755,176
Previous $1.46 Million 50.24%
% of portfolio
0.0%
Previous 0.0%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$1.85 - $3.2 $551,485 - $953,920
-298,100 Reduced 47.26%
332,677 $725,000
Q2 2024

Oct 17, 2024

SELL
$2.31 - $5.59 $1.63 Million - $3.93 Million
-703,561 Reduced 52.73%
630,777 $1.46 Million
Q2 2024

Aug 14, 2024

SELL
$2.31 - $5.59 $1.63 Million - $3.93 Million
-703,561 Reduced 52.73%
630,777 $1.46 Million
Q1 2024

Oct 17, 2024

BUY
$1.9 - $10.13 $1.34 Million - $7.13 Million
703,561 Added 111.54%
1,334,338 $7.34 Million
Q1 2024

Aug 16, 2024

SELL
$1.9 - $10.13 $1.1 Million - $5.88 Million
-580,688 Reduced 30.32%
1,334,338 $7.34 Million
Q1 2024

May 15, 2024

SELL
$1.9 - $10.13 $1.1 Million - $5.88 Million
-580,688 Reduced 30.32%
1,334,338 $7.34 Million
Q4 2023

Aug 16, 2024

BUY
$2.08 - $31.18 $2.67 Million - $40 Million
1,284,249 Added 203.6%
1,915,026 $4.73 Million
Q4 2023

Feb 13, 2024

BUY
$2.08 - $31.18 $3.39 Million - $50.9 Million
1,630,919 Added 574.05%
1,915,026 $4.73 Million
Q3 2023

Nov 15, 2023

SELL
$29.8 - $40.3 $6.86 Million - $9.28 Million
-230,184 Reduced 44.76%
284,107 $9.87 Million
Q2 2023

Aug 14, 2023

SELL
$28.53 - $39.55 $2.33 Million - $3.23 Million
-81,585 Reduced 13.69%
514,291 $16.9 Million
Q1 2023

May 15, 2023

BUY
$29.51 - $46.65 $14.1 Million - $22.2 Million
476,662 Added 399.84%
595,876 $20 Million
Q4 2022

Feb 14, 2023

BUY
$24.16 - $36.38 $880,607 - $1.33 Million
36,449 Added 44.04%
119,214 $3.91 Million
Q3 2022

Nov 14, 2022

BUY
$12.64 - $38.7 $802,791 - $2.46 Million
63,512 Added 329.88%
82,765 $2.89 Million
Q2 2022

Oct 27, 2022

BUY
$11.95 - $18.75 $149,805 - $235,050
12,536 Added 186.63%
19,253 $236,000
Q2 2022

Aug 15, 2022

BUY
$11.95 - $18.75 $149,805 - $235,050
12,536 Added 186.63%
19,253 $236,000
Q1 2022

Oct 27, 2022

SELL
$10.0 - $19.98 $125,360 - $250,469
-12,536 Reduced 65.11%
6,717 $91,000
Q1 2022

May 13, 2022

SELL
$10.0 - $19.98 $690 - $1,378
-69 Reduced 1.02%
6,717 $91,000
Q4 2021

Feb 14, 2022

BUY
$14.2 - $23.07 $96,361 - $156,553
6,786 New
6,786 $135,000

Others Institutions Holding VTYX

About Ventyx Biosciences, Inc.


  • Ticker VTYX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 56,527,200
  • Market Cap $128M
  • Description
  • Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis...
More about VTYX
Track This Portfolio

Track Morgan Stanley Portfolio

Follow Morgan Stanley and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.